FTSE MIB
33.939,75 -331,37 (-0,97%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,96 +0,39 (+0,47%) Bitcoin EUR
59.947,93 +66,79 (+0,11%)
Precipio, Inc. (PRPO)
| Chiusura precedente | 5,97 |
| Aperto | 5,71 |
| Denaro | 5,23 x 100 |
| Lettera | 7,12 x 100 |
| Min-Max giorno | 5,71 - 6,30 |
| Intervallo di 52 settimane | 4,75 - 14,80 |
| Volume | |
| Media Volume | 5.212 |
| Capitalizzazione | 8,832M |
| Beta (5 anni mensile) | 1,25 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,51 |
| Prossima data utili | 15 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 19,00 |
GlobeNewswirePrecipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Company anticipates current cash levels sufficient to reach breakevenNEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives has reduced Cash Burn From Operations (CBFO) by 59% compared to the same quarter last year, from approximately $2.5M/quarter to $1M/quarter. Management has set a target of reaching financial independence with its current cash reserve
- GlobeNewswire
Precipio Continues to Sign New HemeScreen™ Customers
New customer orders received in Q3 exceed $1M annualized revenueNEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M. In a recent announcement, the company announced that the product revenue necessary to reach cash flow breakeven has been reduced to $6M annualized run rate, or $1.5M/quarter. As of today, Precipio forecasts
- GlobeNewswire
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6MNEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required from the products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates. This m
